Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.
Researchers funded by Cancer Research UK have been looking at why new drugs called "MEK inhibitors", which are currently being tested in clinical trials, aren't as effective at killing cancer cells as they should be.
They discovered that MITF - a protein that helps cells to produce pigment but also helps melanoma cells to grow and survive - is able to provide cancer cells with a resistance to MEK inhibitors.
Dr Claudia Wellbrock and her team at the Wellcome Trust Centre for Cell-Matrix Research compared human melanoma cells that respond to the drug to cells that don't. They discovered that the cells that didn't respond to the drug contained higher levels of the protein SMURF2.
The researchers reduced the level of SMURF2 in the melanoma cancer cells and then treated the tumour with the MEK inhibitor. They found a 100 fold increase in the sensitivity of the cells to the drug. It appears that removing SMURF2 radically decreases the level of MITF in melanoma cells, making the MEK inhibitor a lot more powerful.
Using mice with tumours the team found that over a three week period there was a substantial decrease in tumour growth when the removal of SMURF2 was used in combination with MEK inhibitors.
Dr Wellbrock says: "Much of cancer research is now focussed on finding new drug combinations. It's recognised that cancers frequently find new ways to combat even the most novel and highly efficient drug treatments, so we are now focussing on targeting the mechanisms that allow the cancer cells to overcome the drug effects. We're very excited about the potential for this new approach that has proved to be so effective in our experiments."
One of the drawbacks of the MEK inhibitor drug is that it targets all cells. MEK (MAP/ERK kinase protein) is present in all cells but cancer cells have overactive MEK. This means the drug must be used in small doses and for a lengthy period to avoid harming healthy cells. By reducing SMURF2 to increase the drug's effectiveness smaller doses could be given over a shorter time period, reducing the level of toxicity in healthy cells.
Dr Wellbrock says: "If we can reduce the toxicity to all cells it will mean cancer treatments are less harmful to patients. It's vital that we improve the treatments for melanoma which is the fifth most common cancer in the UK. By the time many people are diagnosed with melanoma the cancer has already started to spread and advanced tumours can be highly resistant to conventional cancer treatments. The development of resistance to new drugs has also been a major drawback. If we can identify more potent and less toxic drug combinations to tackle melanoma then we could save thousands of lives."
This study was funded in part by Cancer Research UK and the results have been published in the Journal of the National Cancer Institute.
Talking about the research Dr Julie Sharp from the charity said: "Recently there have been some really exciting developments in treating melanoma – but new approaches that tackle the problem of resistance are still needed. This type of research will be a key focus of the planned new Manchester Cancer Research Centre which will bring together a wide range of research expertise to revolutionise cancer treatment."
The next step for Dr Wellbrock will be to find a drug that can reduce the activity of SMURF2 in cancer cells. The Manchester research team are now screening drug libraries for an existing drug that may already be approved for use for a different illness.
It's hoped that identifying a drug to use in combination with MEK inhibitors will provide a much more powerful and ultimately more successful approach to treating melanoma.
University of Manchester: http://www.manchester.ac.uk
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
A Mirror Online report on a breast cancer patient who refused medical treatment for so-called natural alternatives ignores the health risks
From Adam and Eve to Snakes on a Plane, legend and pop culture confirms all that slithers is just a little bit creepy. Andrew McGibbon has made it his mission to change people’s minds, highlighting snakes’ beauty and elegance in his series Slitherstition.
Just a rash? Not if you have eczema. People with eczema often have a hard time finding appropriate health care and are apt to miss work dealing with the chronic skin problem, a study finds.
The technique aims to rejuvenate a woman's eggs using mitochondria from cells extracted from her ovaries. A Toronto clinic's first births are due soon, and some doctors are worried about side effects.
Findings published in The Lancet show chance of heart attack drops by 48% when people most at risk take cholesterol-lowering medications
Paranoid fears are common and have a variety of causes but new research shows specific issue cognitive behaviour therapy can bring significant benefits
Popular belief has it that human ‘sex pheromones’ exist and are well-established by the scientific community. But all is not as it seems, as Tristram Wyatt explains
Toward the end of World War II, the Nazis blocked all food and fuel supplies to the Netherlands, leading to famine. Many babies born during this famine suffered long-term effects, including a higher incidence of a variety of conditions such as heart disease, obesity, glucose intolerance, and obstructed airways.
Your girlfriend is right. Adults can expect to get flu only twice every 10 years, suggests an analysis of the antibodies in people's blood
Drinking a few cups of coffee a day may help people avoid clogged arteries - a known risk factor for heart disease - South Korean researchers believe.